IDEXX Laboratories, Inc. $IDXX Shares Acquired by Mather Group LLC.

Key Points

• Mather Group LLC increased its holdings in IDEXX Laboratories by 92.4% during the second quarter, now owning 1,462 shares valued at approximately $784,000.
• Several large investors, including B. Riley Wealth Advisors and Wellington Management Group, also significantly raised their stakes in IDEXX, with hedge funds owning 87.84% of the stock.
• IDEXX Laboratories reported a quarterly EPS of $3.63, exceeding analyst estimates, and set FY 2025 guidance at $12.400-12.760 EPS.

Mather Group LLC. increased its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 92.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,462 shares of the company's stock after purchasing an additional 702 shares during the period. Mather Group LLC.'s holdings in IDEXX Laboratories were worth $784,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in IDXX. B. Riley Wealth Advisors Inc. grew its holdings in IDEXX Laboratories by 97.0% in the 4th quarter. B. Riley Wealth Advisors Inc. now owns 1,838 shares of the company's stock valued at $760,000 after buying an additional 905 shares during the period. Centaurus Financial Inc. grew its holdings in IDEXX Laboratories by 23.3% in the fourth quarter. Centaurus Financial Inc. now owns 280 shares of the company's stock valued at $116,000 after purchasing an additional 53 shares during the period. Lansforsakringar Fondforvaltning AB publ purchased a new stake in IDEXX Laboratories in the fourth quarter valued at approximately $11,226,000. 111 Capital acquired a new position in IDEXX Laboratories during the fourth quarter worth approximately $866,000. Finally, Wellington Management Group LLP raised its stake in IDEXX Laboratories by 161.2% during the fourth quarter. Wellington Management Group LLP now owns 195,369 shares of the company's stock worth $80,773,000 after purchasing an additional 120,558 shares during the period. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other IDEXX Laboratories news, EVP Michael Lane sold 8,411 shares of the company's stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $627.74, for a total value of $5,279,921.14. Following the completion of the transaction, the executive vice president directly owned 7,132 shares of the company's stock, valued at $4,477,041.68. This represents a 54.11% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Nimrata Hunt sold 7,143 shares of the firm's stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $630.43, for a total value of $4,503,161.49. Following the sale, the executive vice president owned 18,007 shares of the company's stock, valued at $11,352,153.01. This represents a 28.40% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 54,057 shares of company stock valued at $34,293,468. Corporate insiders own 0.98% of the company's stock.

IDEXX Laboratories Price Performance

Shares of NASDAQ IDXX opened at $618.17 on Friday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.11 and a quick ratio of 0.79. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $688.12. The company has a market capitalization of $49.45 billion, a price-to-earnings ratio of 51.47, a PEG ratio of 4.06 and a beta of 1.56. The business has a 50-day moving average of $623.25 and a 200-day moving average of $525.93.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The company reported $3.63 EPS for the quarter, topping the consensus estimate of $3.28 by $0.35. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The firm had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.06 billion. During the same period in the previous year, the company posted $2.44 EPS. IDEXX Laboratories's revenue for the quarter was up 10.6% on a year-over-year basis. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. On average, equities analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Analyst Ratings Changes

IDXX has been the subject of several research reports. Morgan Stanley boosted their price objective on shares of IDEXX Laboratories from $722.00 to $765.00 and gave the company an "overweight" rating in a research note on Friday, August 15th. Piper Sandler reiterated a "neutral" rating and issued a $700.00 target price (up previously from $510.00) on shares of IDEXX Laboratories in a report on Monday, August 11th. Leerink Partners upped their price target on IDEXX Laboratories from $580.00 to $600.00 and gave the stock an "outperform" rating in a research note on Thursday, July 17th. JPMorgan Chase & Co. raised their price objective on IDEXX Laboratories from $550.00 to $675.00 and gave the stock an "overweight" rating in a report on Monday, August 4th. Finally, BTIG Research boosted their target price on IDEXX Laboratories from $545.00 to $785.00 and gave the stock a "buy" rating in a report on Tuesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and three have issued a Hold rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $649.44.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.